An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease
IntroductionAging is the primary risk factor for sporadic Alzheimer's disease. Chronic low-grade inflammation associated with aging drives cognitive impairment through multiple mechanisms involving oxidative stress, insulin resistance, and dysregulation of metabolic, immunologic, and hematologi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2025.1516746/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850146399970131968 |
|---|---|
| author | Christopher L. Reading Jiayan Yan Marcia A. Testa Donald C. Simonson Hira Javaid Lisa Schmunk Daniel E. Martin-Herranz Robert Brooke Juozas Gordevicius Jeffrey Zhang Harvey Yuan Clarence Ahlem Lixia Wang Penelope Markham Nily Osman Stephen O'Quinn Joseph Palumbo |
| author_facet | Christopher L. Reading Jiayan Yan Marcia A. Testa Donald C. Simonson Hira Javaid Lisa Schmunk Daniel E. Martin-Herranz Robert Brooke Juozas Gordevicius Jeffrey Zhang Harvey Yuan Clarence Ahlem Lixia Wang Penelope Markham Nily Osman Stephen O'Quinn Joseph Palumbo |
| author_sort | Christopher L. Reading |
| collection | DOAJ |
| description | IntroductionAging is the primary risk factor for sporadic Alzheimer's disease. Chronic low-grade inflammation associated with aging drives cognitive impairment through multiple mechanisms involving oxidative stress, insulin resistance, and dysregulation of metabolic, immunologic, and hematologic systems.MethodsIn a 7-month, randomized, double-blind, placebo-controlled trial (NCT04669028), we investigated the safety and activity of bezisterim, a first-in-class, oral, blood–brain barrier–permeable, anti-inflammatory agent on cognitive, molecular, biochemical, physiological, and biological aging parameters in a subset of 50 mild-to-moderate probable Alzheimer's disease participants. These participants had source-document-verified clinical measures and samples, and they completed the protocol. This study focuses on epigenetic, metabolic, biomarker, and cognitive measures in the exploratory biomarker population that completed the protocol.ResultsBezisterim was associated with non-significant directional improvements in multiple measures of cognitive and functional performance compared to placebo, with correlations to biological age (determined by DNA methylation “clocks”) and to metabolism, inflammation, and dementia biomarkers. In addition, clinical measures correlated with the extent of DNA methylation of certain cytosine-phosphate-guanine (CpG) sites in genes associated with metabolic inflammation and neurodegeneration.DiscussionThe results suggest the possible use of bezisterim to target the multifactorial processes underlying dementia.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04669028, Identifier: NCT04669028. |
| format | Article |
| id | doaj-art-dd0bc5bca5f84c6e8c557615b87c0a8b |
| institution | OA Journals |
| issn | 1662-453X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj-art-dd0bc5bca5f84c6e8c557615b87c0a8b2025-08-20T02:27:50ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-05-011910.3389/fnins.2025.15167461516746An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's diseaseChristopher L. Reading0Jiayan Yan1Marcia A. Testa2Donald C. Simonson3Hira Javaid4Lisa Schmunk5Daniel E. Martin-Herranz6Robert Brooke7Juozas Gordevicius8Jeffrey Zhang9Harvey Yuan10Clarence Ahlem11Lixia Wang12Penelope Markham13Nily Osman14Stephen O'Quinn15Joseph Palumbo16BioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, United StatesDivision of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United StatesHurdle.bio/Chronomics Ltd., London, United KingdomHurdle.bio/Chronomics Ltd., London, United KingdomHurdle.bio/Chronomics Ltd., London, United KingdomEpigenetic Clock Development Foundation, Torrance, CA, United StatesEpigenetic Clock Development Foundation, Torrance, CA, United StatesPrinceton Pharmatech, Princeton, NJ, United StatesPrinceton Pharmatech, Princeton, NJ, United StatesBioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesBioVie Inc., Carson City, NV, United StatesIntroductionAging is the primary risk factor for sporadic Alzheimer's disease. Chronic low-grade inflammation associated with aging drives cognitive impairment through multiple mechanisms involving oxidative stress, insulin resistance, and dysregulation of metabolic, immunologic, and hematologic systems.MethodsIn a 7-month, randomized, double-blind, placebo-controlled trial (NCT04669028), we investigated the safety and activity of bezisterim, a first-in-class, oral, blood–brain barrier–permeable, anti-inflammatory agent on cognitive, molecular, biochemical, physiological, and biological aging parameters in a subset of 50 mild-to-moderate probable Alzheimer's disease participants. These participants had source-document-verified clinical measures and samples, and they completed the protocol. This study focuses on epigenetic, metabolic, biomarker, and cognitive measures in the exploratory biomarker population that completed the protocol.ResultsBezisterim was associated with non-significant directional improvements in multiple measures of cognitive and functional performance compared to placebo, with correlations to biological age (determined by DNA methylation “clocks”) and to metabolism, inflammation, and dementia biomarkers. In addition, clinical measures correlated with the extent of DNA methylation of certain cytosine-phosphate-guanine (CpG) sites in genes associated with metabolic inflammation and neurodegeneration.DiscussionThe results suggest the possible use of bezisterim to target the multifactorial processes underlying dementia.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04669028, Identifier: NCT04669028.https://www.frontiersin.org/articles/10.3389/fnins.2025.1516746/fullAlzheimer'sneuroinflammationinsulinagingDNA methylationbezisterim |
| spellingShingle | Christopher L. Reading Jiayan Yan Marcia A. Testa Donald C. Simonson Hira Javaid Lisa Schmunk Daniel E. Martin-Herranz Robert Brooke Juozas Gordevicius Jeffrey Zhang Harvey Yuan Clarence Ahlem Lixia Wang Penelope Markham Nily Osman Stephen O'Quinn Joseph Palumbo An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease Frontiers in Neuroscience Alzheimer's neuroinflammation insulin aging DNA methylation bezisterim |
| title | An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease |
| title_full | An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease |
| title_fullStr | An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease |
| title_full_unstemmed | An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease |
| title_short | An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease |
| title_sort | exploratory analysis of bezisterim treatment associated with decreased biological age acceleration and improved clinical measure and biomarker changes in mild to moderate probable alzheimer s disease |
| topic | Alzheimer's neuroinflammation insulin aging DNA methylation bezisterim |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2025.1516746/full |
| work_keys_str_mv | AT christopherlreading anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT jiayanyan anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT marciaatesta anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT donaldcsimonson anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT hirajavaid anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT lisaschmunk anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT danielemartinherranz anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT robertbrooke anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT juozasgordevicius anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT jeffreyzhang anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT harveyyuan anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT clarenceahlem anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT lixiawang anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT penelopemarkham anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT nilyosman anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT stephenoquinn anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT josephpalumbo anexploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT christopherlreading exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT jiayanyan exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT marciaatesta exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT donaldcsimonson exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT hirajavaid exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT lisaschmunk exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT danielemartinherranz exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT robertbrooke exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT juozasgordevicius exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT jeffreyzhang exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT harveyyuan exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT clarenceahlem exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT lixiawang exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT penelopemarkham exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT nilyosman exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT stephenoquinn exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease AT josephpalumbo exploratoryanalysisofbezisterimtreatmentassociatedwithdecreasedbiologicalageaccelerationandimprovedclinicalmeasureandbiomarkerchangesinmildtomoderateprobablealzheimersdisease |